CYTK - Cytokinetics, Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.60
-0.05 (-0.58%)
At close: 4:00PM EDT

8.60 0.00 (0.00%)
After hours: 5:10PM EDT

Stock chart is not supported by your current browser
Previous Close8.65
Open8.65
Bid8.00 x 4000
Ask9.35 x 3000
Day's Range8.60 - 8.75
52 Week Range6.75 - 15.95
Volume151,577
Avg. Volume331,712
Market Cap466.099M
Beta1.77
PE Ratio (TTM)N/A
EPS (TTM)-2.52
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.71
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA

    Cure SMA and Cytokinetics today announced an expanded partnership to increase education, awareness and fundraising for spinal muscular atrophy (SMA).  As a National Platinum Partner for 2018, Cytokinetics will lend support to several of Cure SMA’s initiatives at both the local and national level to advance understanding of, and research toward potential treatments for SMA, a genetic disease that robs people of physical strength and takes away their ability to walk, eat or breathe. Cytokinetics will sponsor the 2018 Annual SMA Conference as a Visionary Sponsor, increasing support for this unique event which brings together families affected by SMA, along with researchers and clinicians, to network, learn, and collaborate.

  • GlobeNewswire12 days ago

    Cytokinetics to Hold Annual Meeting of Stockholders

    Cytokinetics, Incorporated (CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 16, 2018 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum, President and Chief Executive Officer, is scheduled to present an overview of Cytokinetics’ performance. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.

  • GlobeNewswire21 days ago

    Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS

    Cytokinetics, Incorporated (CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. “We have enjoyed our longstanding, successful collaboration with The ALS Association and look forward to continuing our partnership to support the ALS community,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.

  • ACCESSWIRE22 days ago

    Blog Exposure - Zealand’s End-of-Phase-2 Meeting with FDA Confirmed the Path Forward for Phase-3 Program of Glepaglutide for Short Bowel Syndrome

    LONDON, UK / ACCESSWIRE / April 30, 2018 / Active-Investors.com has just released a free research report on Zealand Pharma A/S (NASDAQ: ZEAL) ("Zealand"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZEAL as the Company's latest news hit the wire. On April 26, 2018, the Company announced that it has successfully concluded the End-of-Phase-2 meeting with the US Food and Drug Administration (FDA) regarding the Phase-3 program for Zealand's long-acting GLP-2 analog, glepaglutide, in short bowel syndrome (SBS) patients.

  • Thomson Reuters StreetEvents23 days ago

    Edited Transcript of CYTK earnings conference call or presentation 26-Apr-18 8:30pm GMT

    Q1 2018 Cytokinetics Inc Earnings Call

  • Associated Press26 days ago

    Cytokinetics: 1Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 56 cents per share. The biopharmaceutical company posted revenue of $5.3 million in the period. Cytokinetics shares have declined ...

  • GlobeNewswire26 days ago

    Cytokinetics, Inc. Reports First Quarter 2018 Financial Results

    Completed Enrollment in Phase 2 Study of Reldesemtiv in Patients with SMA; Data Expected in Q2 2018. Preparing to Initiate Second Phase 3 Clinical Trial of Omecamtiv Mecarbil. SOUTH SAN FRANCISCO, Calif., ...

  • Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value?
    Simply Wall St.26 days ago

    Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value?

    Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Cytokinetics Incorporated (NASDAQ:CYTK) as an investment opportunity. Anyone interested inRead More...

  • GlobeNewswire28 days ago

    Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference

    Cytokinetics, Incorporated (CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented by John Day, M.D., Ph.D., Professor of Neurology and Pediatrics (Genetics), Stanford University Medical Center, in an oral presentation at the 2018 Annual Cure SMA Conference in Dallas on June 16, 2018. The clinical study is designed to assess the effect of reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA), on multiple measures of muscle function in both ambulatory and non-ambulatory patients with SMA. In collaboration with Astellas Pharma Inc. (TSE:4503) (“Astellas”), Cytokinetics is developing reldesemtiv as a potential treatment for people living with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

  • GlobeNewswirelast month

    Cytokinetics to Announce First Quarter Results on April 26, 2018

    SOUTH SAN FRANCISCO, Calif., April 12, 2018-- Cytokinetics, Incorporated today announced that it is scheduled to report first quarter results on April 26, 2018 at 4:00 PM Eastern Time. Following the announcement, ...

  • GlobeNewswire3 months ago

    Cytokinetics to Present at March Investor Conferences

    SOUTH SAN FRANCISCO, Calif., March 05, 2018-- Cytokinetics, Incorporated announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following ...

  • GlobeNewswire3 months ago

    Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

    SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018-- Cytokinetics, Incorporated today announced that it is joining the global initiative to raise awareness of Rare Disease Day ®, an international campaign led ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMT

    Q4 2017 Cytokinetics Inc Earnings Call

  • Associated Press3 months ago

    Cytokinetics reports 4Q loss

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 75 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed ...

  • ACCESSWIRE3 months ago

    Cytokinetics, Incorporated to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 15, 2018 / Cytokinetics, Incorporated (NASDAQ: CYTK ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 15, 2018 at 4:30 PM ...

  • What You Must Know About Cytokinetics Incorporated’s (NASDAQ:CYTK) Major Investors
    Simply Wall St.3 months ago

    What You Must Know About Cytokinetics Incorporated’s (NASDAQ:CYTK) Major Investors

    Today, I will be analyzing Cytokinetics Incorporated’s (NASDAQ:CYTK) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, the impactRead More...

  • Benzinga3 months ago

    Cytokinetics Earnings Outlook

    Cytokinetics (NASDAQ: CYTK ) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement. Earnings and Revenue Sell-side analysts ...